Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: Effect of antiviral treatment

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 10, 2014, Pages 1146-1151

  Maconi, Giovanni ^a   Lombardini, Marta ^a   Furfaro, Federica ^a   Bezzio, Cristina ^a   Zerbi, Pietro ^a   Ardizzone, Sandro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiviral treatment; Crohn's disease; Cytomegalovirus infection; Inflammatory bowel diseases; Outcome; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; GANCICLOVIR; INFLIXIMAB; METRONIDAZOLE; STEROID; VALGANCICLOVIR; VIRUS ANTIGEN; ANTIVIRUS AGENT;

ACTIVE COLITIS; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; COHORT ANALYSIS; COLITIS; COLON BIOPSY; COLON RESECTION; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RELAPSE; REMISSION; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; VIRUS LOAD; AGED; COLITIS, ULCERATIVE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; MIDDLE AGED; PATHOGENICITY; TIME; TREATMENT OUTCOME; VIRUS ACTIVATION;

ADULT; AGED; ANTIVIRAL AGENTS; COLECTOMY; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84927695853     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000175     Document Type: Article

References (25)

1. Kandile A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006; 101:2857-2865.
2. Vega R, Bertrán X, Menacho M, Domènech E, Moreno de Vega V, Hombrados M, et al. Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94:1053-1056.
3. Cottone M, Pietrosi G, Martorana G, Casà A, Pecoraro G, Oliva L, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001; 96:773-775.
4. Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96:2137-2142.
5. Wada Y, Matsui T, Matake H, Sakurai T, Yamamoto J, Kikuchi Y, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum 2003; 46 (Suppl 10):S59-S65.
6. Criscuoli V, Casà A, Orlando A, Pecoraro G, Oliva L, Traina M, et al. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis 2004; 36:818-820.
7. Yoshino T, Nakase H, Ueno S, Uza N, Inoue S, Mikami S, et al. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis 2007; 13:1516-1521.
8. Matsuoka K, Iwao Y, Mori T, Sakuraba A, Yajima T, Hisamatsu T, et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 2007; 102:331-337.
9. Criscuoli V, Rizzuto MR, Montalbano L, Gallo E, Cottone M. Natural history of cytomegalovirus infection in a series of patients with moderate-severe acute ulcerative colitis. World J Gastroenterol 2011; 17:633-638.
10. Delvincourt M, Lopez A, Pillet S, Burrier A, Selsik P, Cosnes J, et al. The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. Aliment Pharmacol Ther 2014; 39:712-720.
11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625-1629.
12. Charlson C, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383.
13. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19:5A-36A.
14. Antonelli E, Baldoni M, Giovenali P, Villanacci V, Essatari M, Bassotti G. Intestinal superinfections in patients with inflammatory bowel diseases. J Crohns Colitis 2012; 6:154-159.
15. Maconi G, Colombo E, Zerbi P, Sampietro GM, Fociani P, Bosani M, et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis 2005; 37:418-423.
16. Kim YS, Kim YH, Kim JS, Cheon JH, Ye BD, Jung SA, et al. IBD Study Group of the Korean Association for the Study of Intestinal Diseases. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol 2012; 46:51-56.
17. Kopylov U, Sasson G, Geyshis B, Oikawa MT, Barshack I, Eliakim R, Ben-Horin S. Cytomegalovirus positive ulcerative colitis: a single center experience and literature review. World J Gastrointest Pathophysiol 2013; 4:18-23.
18. Kim JJ, Simpson N, Klipfel N, Debose R, Barr N, Laine L. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci 2010; 55:1059-1065.
19. Al-Zafiri R, Gologan A, Galiatsatos P, Szilagyi A. Cytomegalovirus complicating inflammatory bowel disease: a 10-year experience in a community-based, university-affiliated hospital. Gastroenterol Hepatol (NY) 2012; 8:230-239.
20. Kopylov U, Eliakim-Raz N, Szilagy A, Seidman E, Ben-Horin S, Katz L. Antiviral therapy in cytomegalovirus-positive ulcerative colitis: a systematic review and meta-analysis. World J Gastroenterol 2014; 20:2695-2703.
21. Roblin X, Pillet S, Oussalah A, Berthelot P, Del Tedesco E, Phelip JM, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol 2011; 106:2001-2008.
22. D'Ovidio V, Vernia P, Gentile G, Capobianchi A, Marcheggiano A, Viscido A, et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J Clin Virol 2008; 43:180-183.
23. Nakase H, Matsumura K, Yoshino T, Chiba T. Systematic review: cytomegalovirus infection in inflammatory bowel disease. J Gastroenterol 2008; 43:735-740.
24. Lévêque N, Brixi-Benmansour H, Reig T, Renois F, Talmud D, Brodard V, et al. Low frequency of cytomegalovirus infection during exacerbations of inflammatory bowel diseases. J Med Virol 2010; 82:1694-1700.
25. Garrido E, Carrera E, Manzano R, Lopez-Sanroman A. Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease. World J Gastroenterol 2013; 19:17-25.